CIMT 2021 - Annual Meeting of the Association for Cancer Immunotherapy (Virtual Meeting)
May 10 - May 12, 2021 | MainzGermany
LARVOL is not affiliated with Annual Meeting of the Association for Cancer Immunotherapy (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 17 abstracts linked to Trials
[VIRTUAL] T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
[VIRTUAL] Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients.
[VIRTUAL] Preliminary immunogenicity analysis of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with advanced HPV16+ cancers
[VIRTUAL] IVAC-ALL-1: Updated analysis of a phase I/II clinical trial on personalized peptide vaccination based on patient-individual tumor-specific variants in relapsed pediatric acute lymphoblastic leukemia
[VIRTUAL] Ipilimumab, maraviroc and nivolumab in advanced metastatic colorectal and pancreatic cancer. Preliminary results from the phase 1 LUMINESCENCE trial.
[VIRTUAL] Talimogene laherparepvec (T-VEC)-induced tumor oncolysate as a source of tumor antigens and maturation factors for blood-isolated myeloid dendritic cells
[VIRTUAL] Adoptive T cell therapy during chemotherapy with or without Interferon-a in patients with recurrent ovarian cancer.
[VIRTUAL] BNT211: A phase I/IIa trial to evaluate safety and efficacy of CLDN6 CAR-T and CARVac-based in vivo expansion to improve treatment of patients with CLDN6-positive advanced solid tumors.
[VIRTUAL] Monitoring the immune activation in recurrent glioblastoma patients treated with Nivolumab and Bevacizumab
[VIRTUAL] Longitudinal analysis of anti-tumor T-cell responses in vaccinated glioblastoma patients with improved survival
[VIRTUAL] Immune Cell Type Deconvolution by RNA Sequencing Data
[VIRTUAL] A peptide-based vaccine to induce SARS-CoV-2-specific T cells in cancer patients with disease- or treatment-induced antibody deficiency
[VIRTUAL] An RNA-encoded IL-2 variant with an extended half-life mediates synergistic anti-tumor activity when combined with immune checkpoint blockade
[VIRTUAL] An RNA-encoded IL-2 variant with an extended half-life enhances the anti-tumor activity of RNA-based cancer vaccines
[VIRTUAL] RNA-encoded IL-2 and IL-7 with extended half-lives synergize to modulate T cell responses and enhance anti-tumor efficacy